title: Reply to E. C. Smyth et al.
authors: Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA hmamon@lroc.harvard.edu.
authors: Harvey J
authors: HJ
authors: Mamon
authors: Lineberger Cancer Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors: Joel E
authors: JE
authors: Tepper
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000628:therapy*; D016629:Esophagectomy; D004943:Esophagogastric Junction; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D013274:Stomach Neoplasms / Q000628:therapy*